AZN News and Press, AstraZeneca PLC From 05/29/24

2024-05-29 16:54:54 ET More on Fusion Pharmaceuticals What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Fusion Pharmaceuticals GAAP EPS of -$0.39 misses by $0.06 Ast...

2024-05-29 13:01:37 ET More on Amgen, AstraZeneca Amgen Stock: Poised To Break Out (Technical Analysis) AstraZeneca, Amgen release mid-stage data on Tezspire for COPD Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo Amgen, Inc. (AMGN) ATS...

2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...

2024-05-29 10:07:00 ET As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with billions of dollars devoted to research and development, it...

2024-05-29 08:06:00 ET AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global biopharma sector, and its investors could potentially be wealt...

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 •  Conference call and webcast sched...

2024-05-28 12:29:50 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Nona Biosciences and AstraZeneca sign glo...

In the overall trial population, survival results numerically favoured AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan but did not reach statistical significance TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the ...

2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...

2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...